Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2 inhibitor, across multiple cancer types, including relapsed and refractory (R/R) myelofibrosis (MF), Merkel cell carcinoma (MCC), and other malignancies. Using a PK model based on 318 subjects, researchers found that tumor type influenced navtemadlin’s absorption, clearance, and exposure, with factors … Continued